blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3394070

EP3394070 - CRYSTALLINE FORMS OF QUINOLONE ANALOGS AND THEIR SALTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.06.2024
Database last updated on 28.03.2026
FormerThe patent has been granted
Status updated on  30.06.2023
FormerGrant of patent is intended
Status updated on  14.02.2023
FormerExamination is in progress
Status updated on  12.02.2021
FormerRequest for examination was made
Status updated on  28.09.2018
FormerThe international publication has been made
Status updated on  23.06.2017
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Senhwa Biosciences, Inc.
10F, No. 225, Sec. 3
Peihsin Rd.
Hsintien Dist.
New Taipei City 23143 / TW
[2023/31]
Former [2019/18]For all designated states
Senhwa Biosciences, Inc.
10F, No. 225, Sec. 3
Peishin Rd.
Hsintien Dist.
New Taipei City 23143 / TW
Former [2018/44]For all designated states
Senhwa Biosciences, Inc.
9F, No.205-1, Section 3
Peishin Road
Hsintien District
New Taipei City 23143 / TW
Inventor(s)01 / RYCKMAN David M.
5675 Willowmere Lane
San Diego, CA 92130 / US
02 / YU Iching Grace
4223 Calle Mejillones
San Diego, CA 92130 / US
03 / LIU Hshiou-Ting
1552 Portola Drive
Milpitas, CA 95035 / US
 [2018/44]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[2023/31]
Former [2018/44]Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS / GB
Application number, filing date15910869.514.12.2015
[2018/44]
WO2015US65443
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017105382
Date:22.06.2017
Language:EN
[2017/25]
Type: A1 Application with search report 
No.:EP3394070
Date:31.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 22.06.2017 takes the place of the publication of the European patent application.
[2018/44]
Type: B1 Patent specification 
No.:EP3394070
Date:02.08.2023
Language:EN
[2023/31]
Search report(s)International search report - published on:KR22.06.2017
(Supplementary) European search report - dispatched on:EP10.04.2019
ClassificationIPC:C07D513/14, A61K31/4375, A61P35/00
[2019/19]
CPC:
C07D513/14 (EP,KR); A61K31/429 (KR); A61K31/4375 (KR);
A61K31/551 (KR); A61P35/00 (EP,KR); C07B2200/13 (KR)
Former IPC [2018/44]C07D513/14, C07D471/14, C07D403/12, C07D403/14, A61K31/4375, A61K31/429, A61K31/551
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/44]  
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:KRISTALLINE FORMEN VON CHINOLINANALOGA UND DEREN SALZEN[2018/44]
English:CRYSTALLINE FORMS OF QUINOLONE ANALOGS AND THEIR SALTS[2018/44]
French:FORMES CRISTALLINES D'ANALOGUES DE QUINOLONE ET LEURS SELS[2018/44]
Entry into regional phase10.07.2018National basic fee paid 
10.07.2018Search fee paid 
10.07.2018Designation fee(s) paid 
10.07.2018Examination fee paid 
Examination procedure10.07.2018Examination requested  [2018/44]
10.07.2018Date on which the examining division has become responsible
01.10.2020Amendment by applicant (claims and/or description)
15.02.2021Despatch of a communication from the examining division (Time limit: M06)
11.08.2021Reply to a communication from the examining division
11.10.2022Date of oral proceedings
24.10.2022Despatch of a communication from the examining division (Time limit: M02)
24.10.2022Minutes of oral proceedings despatched
23.12.2022Reply to a communication from the examining division
15.02.2023Communication of intention to grant the patent
22.06.2023Fee for grant paid
22.06.2023Fee for publishing/printing paid
22.06.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23188399.2  / EP4249072
Opposition(s)03.05.2024No opposition filed within time limit [2024/28]
Fees paidRenewal fee
29.06.2018Renewal fee patent year 03
12.12.2018Renewal fee patent year 04
13.12.2019Renewal fee patent year 05
14.12.2020Renewal fee patent year 06
10.11.2021Renewal fee patent year 07
14.11.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY14.12.2015
HU14.12.2015
CZ02.08.2023
HR02.08.2023
MC02.08.2023
PL02.08.2023
RO02.08.2023
RS02.08.2023
SK02.08.2023
SM02.08.2023
TR02.08.2023
NO02.11.2023
GR03.11.2023
IS02.12.2023
IE14.12.2023
[2026/04]
Former [2025/39]CY14.12.2015
HU14.12.2015
CZ02.08.2023
HR02.08.2023
MC02.08.2023
PL02.08.2023
RO02.08.2023
RS02.08.2023
SK02.08.2023
SM02.08.2023
NO02.11.2023
GR03.11.2023
IS02.12.2023
IE14.12.2023
Former [2025/36]CY14.12.2015
CZ02.08.2023
HR02.08.2023
MC02.08.2023
PL02.08.2023
RO02.08.2023
RS02.08.2023
SK02.08.2023
SM02.08.2023
NO02.11.2023
GR03.11.2023
IS02.12.2023
IE14.12.2023
Former [2024/46]CZ02.08.2023
HR02.08.2023
MC02.08.2023
PL02.08.2023
RO02.08.2023
RS02.08.2023
SK02.08.2023
SM02.08.2023
NO02.11.2023
GR03.11.2023
IS02.12.2023
IE14.12.2023
Former [2024/40]CZ02.08.2023
HR02.08.2023
MC02.08.2023
PL02.08.2023
RO02.08.2023
RS02.08.2023
SK02.08.2023
SM02.08.2023
NO02.11.2023
GR03.11.2023
IS02.12.2023
Former [2024/23]CZ02.08.2023
HR02.08.2023
PL02.08.2023
RO02.08.2023
RS02.08.2023
SK02.08.2023
SM02.08.2023
NO02.11.2023
GR03.11.2023
IS02.12.2023
Former [2024/20]HR02.08.2023
PL02.08.2023
RS02.08.2023
SM02.08.2023
NO02.11.2023
GR03.11.2023
IS02.12.2023
Former [2024/10]HR02.08.2023
PL02.08.2023
RS02.08.2023
NO02.11.2023
GR03.11.2023
IS02.12.2023
Former [2024/09]NO02.11.2023
GR03.11.2023
IS02.12.2023
Former [2024/08]NO02.11.2023
GR03.11.2023
Documents cited:Search[I] WO2009046383  (CYLENE PHARMACEUTICALS INC et al.) [I] 1-16 * paragraph [[0291]] *
 [A]   RICHARD J BASTIN ET AL: "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", ORGANIC PROCESS RESEARCH AND DEVELOP, AMERICAN CHEMICAL SOCIETY, US, vol. 4, no. 5, 19 July 2000 (2000-07-19), pages 427 - 435, XP008154792, ISSN: 1083-6160, [retrieved on 20000719], DOI: 10.1021/OP000018U [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1021/op000018u
International search[X] WO2012123938  (TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD et al.) [X] 1-5, 7, 13, 14, 19-21 , 27, 28, 32-37, 41-43 , 47-49, 53-55, 59-61 * See claim 9; and page 50, lines 3-4. *
 [X] WO2015079411  (TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD et al.) [X] 1-5, 7, 13, 14, 19-21 , 27, 28, 32-37, 41-43 , 47-49, 53-55, 59-61 * See page 71, table 2. *
 [A] WO2007022474  (CYLENE PHARMACEUTICALS INC et al.) [A] 1-5, 7, 13, 14, 19-21 , 27, 28, 32-37, 41-43 , 47-49, 53-55, 59-61 * See pages 138-139. *
 [X]   QUIN, JACLYN E. ET AL.: "Targeting the nucleolus for cancer intervention", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1842, 2014, pages 802 - 816, XP028599501 [X] 1-5, 7, 13, 14, 19-21 , 27, 28, 32-37, 41-43 , 47-49, 53-55, 59-61 * . See page 811. *

DOI:   http://dx.doi.org/10.1016/j.bbadis.2013.12.009
 [X]   DRYGIN, DENIS ET AL.: "Targeting the nucleolus for cancer-specific activation of p53", DRUG DISCOVERY TODAY, vol. 19, no. 3, 3 March 2014 (2014-03-03), pages 259 - 265, XP055391787 [X] 1-5, 7, 13, 14, 19-21 , 27, 28, 32-37, 41-43 , 47-49, 53-55, 59-61 * . See table 2, CX5461. *

DOI:   http://dx.doi.org/10.1016/j.drudis.2013.08.012
by applicantUS7928100
 US8853234
   FREIREICH ET AL., CANCER CHEMOTHER REP, vol. 50, 1966, pages 219 - 244 [X] 1-5, 7, 13, 14, 19-21 , 27, 28, 32-37, 41-43 , 47-49, 53-55, 59-61 * . See page 811. *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.